SEC Form 4 · Rule 10b5-1 trading plans
NEUROCRINE BIOSCIENCES INC (NBIX)
- 48Trades filed under a plan
- 12Plan adoption dates stated
- 7Quarterly results prints on file
- 1Trades in the days before a print
In the 2025 filing year, NEUROCRINE BIOSCIENCES INC filed 34 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 11 reporting owners, covering 48 transactions filed under those plans and 458,363 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 34 names a plan in a footnote. 7 results prints are on file in the same window, which is what makes the interval below measurable.
Trades filed under a plan in NEUROCRINE BIOSCIENCES INC 48
- Gano Kyle — 2025-01-15 · S · 4,812 shares
- Gano Kyle — 2025-01-15 · S · 60,188 shares
- GORMAN KEVIN CHARLES — 2025-01-27 · S · 146,105 shares
- ABERNETHY MATT — 2025-01-31 · S · 1,283 shares
- BENEVICH ERIC — 2025-01-31 · S · 1,207 shares
- Boyer David W. — 2025-01-31 · S · 1,104 shares
- Cooke Julie — 2025-01-31 · S · 916 shares
- Cooke Julie — 2025-01-31 · S · 824 shares
- Delaet Ingrid — 2025-01-31 · S · 422 shares
- GORMAN KEVIN CHARLES — 2025-01-31 · S · 2,707 shares
- Gano Kyle — 2025-01-31 · S · 1,541 shares
- Lippoldt Darin — 2025-01-31 · S · 1,250 shares
Plan adoption dates stated in NEUROCRINE BIOSCIENCES INC 12
- 2021-06-10 — stated in 7 filings
- 2022-09-01 — stated in 7 filings
- 2022-09-12 — stated in 1 filing
- 2022-09-13 — stated in 1 filing
- 2022-09-14 — stated in 1 filing
- 2023-03-15 — stated in 10 filings
- 2023-11-29 — stated in 1 filing
- 2024-03-15 — stated in 1 filing
- 2024-06-14 — stated in 1 filing
- 2024-11-07 — stated in 1 filing
- 2024-11-18 — stated in 2 filings
- 2025-02-24 — stated in 1 filing
Quarterly results prints on file in NEUROCRINE BIOSCIENCES INC 7
- 2025-02-06
- 2025-05-05
- 2025-07-30
- 2025-10-28
- 2026-02-11
- 2026-05-05
- 2026-07-30
Trades in the days before a print in NEUROCRINE BIOSCIENCES INC 1
- 3 days before the 2025-02-06 print — 2025-02-03 · S · Delaet Ingrid · 623 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · ABERNETHY MATT · 1,283 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · BENEVICH ERIC · 1,207 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Boyer David W. · 1,104 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Cooke Julie · 916 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Cooke Julie · 824 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Delaet Ingrid · 422 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · GORMAN KEVIN CHARLES · 2,707 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Gano Kyle · 1,541 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Lippoldt Darin · 1,250 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · Onyia Jude · 126 shares
- 6 days before the 2025-02-06 print — 2025-01-31 · S · ROBERTS EIRY · 1,457 shares
Interval to the next reported results date
For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.
- 1Within 5 days of a print
- 13Within 10 days of a print
- 3Shortest interval, in days
- 0Trades with no later print on file
- GORMAN KEVIN CHARLES 2025-01-27 · S · 10 days before the 2025-02-06 print
- ABERNETHY MATT 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Financial Officer
- BENEVICH ERIC 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Commercial Officer
- Boyer David W. 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Corp. Affairs Officer
- Cooke Julie 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Human Resources Officer
- Cooke Julie 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Human Resources Officer
- Delaet Ingrid 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Regulatory Officer
- GORMAN KEVIN CHARLES 2025-01-31 · S · 6 days before the 2025-02-06 print
- Gano Kyle 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Executive Officer
- Lippoldt Darin 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Legal Officer
- Onyia Jude 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Scientific Officer
- ROBERTS EIRY 2025-01-31 · S · 6 days before the 2025-02-06 print · Chief Medical Officer
- Delaet Ingrid 2025-02-03 · S · 3 days before the 2025-02-06 print · Chief Regulatory Officer
Adoption dates, as the filings state them
- 2021-06-10 stated in 7 filings
- 2022-09-01 stated in 7 filings
- 2022-09-12 stated in 1 filing
- 2022-09-13 stated in 1 filing
- 2022-09-14 stated in 1 filing
- 2023-03-15 stated in 10 filings
- 2023-11-29 stated in 1 filing
- 2024-03-15 stated in 1 filing
- 2024-06-14 stated in 1 filing
- 2024-11-07 stated in 1 filing
- 2024-11-18 stated in 2 filings
- 2025-02-24 stated in 1 filing
As the filings state it: “10b5-1 trading plan adopted by the Reporting Person on March 15, 2024”
Reported results dates on file
- 2025-02-06
- 2025-05-05
- 2025-07-30
- 2025-10-28
- 2026-02-11
- 2026-05-05
- 2026-07-30
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 1
- FMC CORP 2
- ELI LILLY & Co 4
- ABEONA THERAPEUTICS INC. 2
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 12
- Lifevantage Corp 1
- IONIS PHARMACEUTICALS INC 29
- VERTEX PHARMACEUTICALS INC / MA 22
- ARROWHEAD PHARMACEUTICALS, INC. 9
Order the document
Every company with plan records →
Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.